LYEL Lyell Immunopharma, Inc
Price Chart
Executive Summary
Lyell Immunopharma announced upcoming presentations of ronde-cel Phase 1/2 safety and translational data at the EHA 2026 Congress, but no clinical results were disclosed. The company's key catalysts remain the PiNACLE trial data expected in H2 2026 and a potential BLA submission in 2027. This is a routine pipeline update with no immediate impact.
Actionable Insight
Monitor EHA 2026 presentations for ronde-cel safety and translational insights. Focus on PiNACLE trial data in H2 2026 and the Phase 3 PiNACLE-H2H trial for future valuation drivers.
Key Facts
- Ronde-cel safety and translational data to be presented at EHA 2026 (June 11-14).
- PiNACLE trial (3L+ LBCL) data expected H2 2026, pivotal data by mid-2027, BLA submission 2027.
- No new clinical data or financial guidance provided in this release.
Financial Impact
No financial impact from this filing; key catalysts are future data readouts.
Risk Factors
- Clinical data may not meet expectations; ronde-cel is still investigational.
- Competition from approved CAR-T therapies (Yescarta, Breyanzi).
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307088 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
today
|
Press Release
| $13.32 awaiting T+20 | awaiting T+20 | — | $13.50 (+1.39%) |
|
Jun 8, 2026
4d ago
|
Press Release
| $11.94 awaiting T+20 | awaiting T+20 | — | $13.50 (+13.11%) |
|
Jun 4, 2026
8d ago
|
Press Release
| $13.02 awaiting T+20 | awaiting T+20 | — | $13.50 (+3.73%) |
|
Apr 24, 2026
7w ago
|
DEFA14A
| $22.62 $16.37 | ▼ −27.63% | ▼ −32.59% | $13.50 (−40.32%) |
|
Apr 15, 2026
8w ago
|
EFFECT
| $23.84 $19.25 | ▼ −19.25% | ▼ −25.30% | $13.50 (−43.37%) |
|
Apr 3, 2026
10w ago
|
S-3
| $21.69 $20.72 | ▼ −4.47% | ▼ −13.45% | $13.50 (−37.76%) |
|
Mar 12, 2026
13w ago
|
Press Release
| $21.25 $24.80 | ▲ +16.71% | ▲ +13.12% | $13.50 (−36.47%) |
|
Mar 9, 2026
13w ago
|
Press Release
| $25.50 $21.78 | ▼ −14.59% | ▼ −11.78% | $13.50 (−47.06%) |
|
Mar 6, 2026
14w ago
|
Insider Cluster
| $22.46 $21.69 | ▼ −3.43% | ▼ −1.38% | $13.50 (−39.89%) |
|
Feb 28, 2026
14w ago
|
Institutional Cluster
| $24.10 $19.29 | ▼ −19.96% | ▼ −12.02% | $13.50 (−43.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access